Patients coinfected with HIV and HBV are at a higher risk of developing chronic HBV infection, severe hepatitis and cirrhosis than HBV-monoinfected patients [1] [2] [3] . In sub-Saharan Africa, the adult prevalence of HBV infection generally exceeds 8% and that of HIV is on average 5%; therefore, HIV-HBV coinfection is likely frequent in this population [1, 4] . Although several recent cross-sectional studies have evaluated HIV-HBV coinfection in sub-Saharan Africa, especially in South Africa [5, 6] , longitudinal studies are lacking and the clinical and public health implications of high rates of HIV-HBV coinfection remain unclear [7, 8] .
Patients coinfected with HIV and HBV are at a higher risk of developing chronic HBV infection, severe hepatitis and cirrhosis than HBV-monoinfected patients [1] [2] [3] . In sub-Saharan Africa, the adult prevalence of HBV infection generally exceeds 8% and that of HIV is on average 5%; therefore, HIV-HBV coinfection is likely frequent in this population [1, 4] . Although several recent cross-sectional studies have evaluated HIV-HBV coinfection in sub-Saharan Africa, especially in South Africa [5, 6] , longitudinal studies are lacking and the clinical and public health implications of high rates of HIV-HBV coinfection remain unclear [7, 8] .
The World Health Organization (WHO) guidelines recommend hepatitis B surface antigen (HBsAg) testing for all HIV-infected patients who are eligible for antiretroviral therapy (ART) in countries with high HBV prevalence [9] . However, HIV-HBV-coinfected Africans are rarely diagnosed with chronic hepatitis because HBsAg tests are often unavailable and/or unaffordable. As a result of poor access to diagnostic tests and effective drugs, HIV-HBV-coinfected patients rarely initiate ART with regimens containing lamivudine (3TC) or emtricitabine (FTC) plus tenofovir disoproxil fumarate (TDF), as recommended by the WHO. Furthermore,
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Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire
Thérèse N'Dri-Yoman 1, 2 , Xavier Anglaret 1, 3 [10] [11] [12] . Although several studies have reported on the prevalence of isolated HBV core antibodies (anti-HBc) and occult HBV in high-income countries [10, [13] [14] [15] [16] , the prevalence of occult HBV infection in sub-Saharan African HIV patients has never been estimated outside of South Africa [11, 12, 17] . The implications of occult HBV infection at the individual and programme levels are unknown. Our objective was to estimate the prevalence of occult HBV infection in untreated HIV-infected adults with CD4 + T-cell counts <500 cells/mm 3 in Abidjan, the economic capital of Côte d'Ivoire, West Africa.
Methods
We conducted a cross-sectional study in four HIV outpatient clinics in Abidjan. The study was approved by the Ethics Committee of the Côte d'Ivoire Ministry of Health. We included all adult patients who presented for care between June and September 2006 and who satisfied the following criteria: HIV type-1 (HIV-1) or HIV-1 plus HIV type-2 infection, no history of ART, last available CD4 + T-cell count <500 cells/mm 3 and informed consent to participate in the study. We collected blood samples after obtaining written informed consent. Clinicians used standardized forms to record sociodemographic characteristics, clinical history and results of clinical examinations (including signs of liver disease).
We performed the following tests on all study participants: complete blood count (MaxM ® Coulter; Beckman Coulter, Fullerton, CA, USA), serum transaminase assays (Cobas ® Integra 400 Plus; Roche Diagnostics, Mannheim, Germany), CD4 + T-cell count count using flow cytometry (Facscalibur ® ; Becton Dickinson, San Jose, CA, USA) and quantification of plasma HIV-1 RNA levels (generic HIV viral load assay with a threshold of detectability 300 copies/ml; Biocentric, Bandol, France). We also screened all patients for HBsAg and anti-HBc (Mini Vidas ® ; Biomerieux, Marcy l'Etoile, France). HBsAg-positive patients were tested for hepatitis B e antigen (HBeAg) and HBeAg antibodies (anti-HBe). Patients who had negative HBsAg and positive anti-HBc results were tested for HBsAg antibodies (anti-HBs). We performed HBV DNA tests in patients who were HBsAgpositive and in patients who were HBsAg-negative, anti-HBc-positive and anti-HBs-negative using the Cobas ® Amplicor HBV Monitor assay (threshold of detectability 35 copies/ml; Roche Diagnostics).
We stratified patients according to HBV serological and virological status. In the univariate analysis, we tested differences between groups using the Kruskal-Wallis test for quantitative variables and the χ 2 test for qualitative variables. We also performed a multivariate analysis of the factors associated with HBsAg positivity, as well as HBsAg negativity with HBV DNA positivity, using backward logistic regression. The variables included in the analysis were sex, age, HIV-1 RNA levels, HBV DNA levels, WHO clinical stage, CD4 + T-cell count and transaminase levels. In the multivariate analysis, we only considered those variables for which the univariate P-value was <0.20. Statistical analyses were performed with SAS ® version 9.1 software (SAS Institute, Inc., Cary, NC, USA).
Results
We included 495 patients, of whom 73% were women. Median age was 35 years (interquartile range [IQR] 29-41 and range 18-66), 97 (20%) patients were illiterate, 171 (35%) had a primary school level education and 225 (45%) had a secondary school level education. Overall, 33 (7%) patients reported having received an HBV vaccine, 17 (3%) had a history of accidental blood exposure, 39 (8%) had a history of blood transfusion and 4 (1%) were known to have chronic active hepatitis at inclusion, including two who had cirrhosis.
The Figure 1 and Table 1 stratify patients according to their HBV serum and DNA test results. Only 23% of patients had never been exposed to the virus (HBsAgnegative, anti-HBc-negative and anti-HBs-negative), 22% were immune to the virus (anti-HBc-positive and anti-HBs-positive), 13% had chronic HBV infection (HBsAg-positive) and 42% had isolated anti-HBc (HBsAg-negative, anti-HBs-negative and anti-HBcpositive). Of these, 51 (10%) had detectable plasma HBV DNA and were thus diagnosed with occult HBV infection. Of the 63 patients with chronic HBV infection (HBsAg-positive), 43 were HBeAg-negative. Among HBeAg-negative and HBeAg-positive patients, respectively, median HBV DNA levels were 3.7 log 10 copies/ml (IQR 2.72-4.44) and 8.8 log 10 copies/ml (IQR 8. 
3).
Of the 33 patients who reported having received an HBV vaccine, 6 (18%) were found to be HBsAg-positive, of whom 2 had detectable HBV DNA (>8 log 10 copies/ ml). Of the 27 vaccinated patients who were HBsAgnegative, 21 (63%) were anti-HBc-positive. Among the latter, only 13 (39%) were anti-HBs-positive and 3 (11%) were diagnosed with occult HBV.
In accordance with the 2006 WHO guidelines, 183 (37%) patients were eligible for ART at the time of the study. Of these, 33 (18%) had chronic HBV infection, 28 (15%) had occult HBV infection and 122 (67%) had isolated anti-HBc and undetectable plasma HBV DNA. Among patients who had detectable HBV DNA and were eligible for ART, 59% were HBsAg-positive and 41% were HBsAg-negative.
In the univariate analysis, chronic HBV infection was associated with male gender (P<0.0001), ART eligibility (P=0.001) and abnormal transaminase values (P=0.002). Occult HBV infection was associated with lower CD4 + T-cell counts (P=0.003), ART eligibility (P=0.001) and abnormal transaminase values (P=0.048) compared with HBsAg negativity and no occult HBV (Table 1) 
Discussion
Among 495 untreated HIV-infected West African adults with CD4 + T-cell counts <500 cells/mm 3 , 13% were HBsAg-positive. The rate of positive HBsAg assays was within ranges published in other African settings, both for HIV-uninfected and HIV-infected adults [7, 8, 11] 13 (21) 14 (13) 10 (10) 20 (13) 12 (24) 
57 (90 In the univariate analysis, we found significant differences between patients with chronic hepatitis and other patients (never exposed, immune, isolated anti-HBc and negative HBV DNA, and occult hepatitis) for the following variables: gender (P<0.0001), antiretroviral therapy (ART) eligibility (P=0.001) and abnormal transaminase values (P=0.003). We found significant differences between patients with occult HBV and other patients (never exposed, immune and isolated anti-HBc with negative HBV DNA) for the following variables: mean CD4 + T-cell count (P=0.003), ART eligibility (P=0.001) and abnormal transaminase values (P=0.05). We found significant differences between patients with chronic hepatitis and patients with occult HBV for the following variables: distribution of plasma HBV DNA values (P<0.0001). IQR, interquartile range; ULN, upper limit of normal.
for HBV. Of note, only 33 (6%) patients reported having received an HBV vaccine, but this rate will likely increase in coming years, as a result of the 2000 Côte d'Ivoire guideline recommendation to vaccinate all children for HBV.
In our study, 10% of patients were diagnosed with occult HBV infection, defined as detectable HBV DNA despite a negative HBsAg test. Occult HBV infection is a rare phenomenon among HIV-negative patients [11] , in whom it is often associated with HCV [13, 14] . HBV infection is much more frequent in the HIV-infected population, as reported over the past 10 years in a wide range of countries, including South Africa [10] [11] [12] 14, [18] [19] [20] [21] [22] . The prevalence of occult HBV infection in our study was within the 9-17% range that was recently reported in South Africa [11, 17] . We did not measure plasma HBV DNA in patients who were antiHBc-negative or in patients who were anti-HBc-positive and anti-HBs-positive because we assumed that the proportion of patients with detectable plasma HBV DNA in these groups was very low [15, 18, 20] . Patients with occult HBV infection had lower plasma HBV DNA levels than HBsAg-positive patients. This finding is consistent with previous studies [10, 20, 22] , but the reason for this is unclear. The difference in HBV DNA levels might have been caused by immune dysfunction, defective mutant strains or S gene mutants that the HBsAg test could not detect, or by a poor performance of the screening tests.
The clinical implications of high rates of occult HBV infection among HIV-infected patients are also unclear. They depend on the answers to two main questions. First, what strategy should be recommended -and what strategy is feasible in resource-limited settings -for HIV-HBV-coinfected patients? Second, should patients with occult HBV infection follow the same guidelines as HBsAg-positive patients?
Regarding the first question, management of HIV-HBV coinfection is difficult in sub-Saharan Africa because HBsAg tests are not routinely available and HBV DNA tests are almost never performed. In this context, one recommendation could be for all HIVinfected patients in countries with high HBV prevalence to initiate ART with regimens containing 3TC or FTC plus TDF, regardless of their HBV status. The costeffectiveness of this approach should be assessed. In this scenario, patients switching to second-line ART should receive HBsAg tests to prevent HIV-HBV-coinfected patients from interrupting HBV treatment [19, 20] . Related questions that remain to be studied include the benefit of initiating HIV-HBV-coinfected patients on ART earlier than currently recommend by the WHO, the effect of treating all HIV-HBV-coinfected patients with 3TC or FTC plus TDF on HBV transmission [23] , and the importance of active HBV-related immune reconstitution inflammatory syndrome among HIV-HBV-coinfected patients [24] .
Second, the best treatment strategy for HIV-infected patients with occult HBV remains unknown. Future prospective cohort studies should compare short-and long-term outcomes in HIV-infected patients with and without occult HBV. If occult HBV is found to have important implications at the individual and/or population levels, HBV DNA tests will have to become available on a wider scale. This demand could increase financial and operational difficulties in sub-Saharan Africa.
While we wait for these studies, our results have an immediate impact on everyday clinical practice. Clinicians in sub-Saharan Africa should realize that a negative HBsAg test result does not remove the possibility of chronic HBV infection. They can use this knowledge to interpret increased transaminase values, to manage ART-related toxicities and to assign individualized firstor second-line ART regimens.
